. Author manuscript; available in PMC: 2016 Sep 15.

Published in final edited form as: Cancer Prev Res (Phila). 2015 Jun 22;8(9):796–806. doi: 10.1158/1940-6207.CAPR-15-0018

Table 1.

Pilot dosing study – 8 weeks ad libitum consumption.

For Erythrocytes For Serum	Control Diet n = 4 n = 5	0.025%EPA+DHA Diet n = 5 n = 6	0.05%EPA+DHA Diet n = 5 n = 7
Erythrocyte EPA	0.19 ± 0.01^a	2.53 ± 0.28^b	1.41 ± 0.11^b

Serum EPA	0.16 ± 0.02^a	1.66 ± 0.09^b	1.05 ± 0.08^b

Erythrocyte DHA	5.59 ± 0.52^a	7.86 ± 0.90	7.99 ± 0.81^b

Serum DHA	5.01 ± 0.38	5.13 ± 0.17	5.51 ± 0.32

Erythrocyte AA	14.5 ± 1.01^a	9.06 ± 0.92^b	10.5 ± 0.80^b

Serum AA	11.6 ± 0.91^a	5.47 ± 0.58^b	7.59 ± 0.51^b

Erythrocyte (EPA + DHA):AA	0.40 ± 0.01^a	1.16 ± 0.09^b	0.89 ± 0.03^b

Serum (EPA + DHA):AA	0.45 ± 0.01^a	1.31 ± 0.15^b	0.88 ± 0.05^b

Erythrocyte n-3: n-6	0.25 ± 0.01^a	0.60 ± 0.04^b	0.52 ± 0.02^b

Serum n-3: n-6	0.31 ± 0.01^a	0.52 ± 0.06^b	0.43 ± 0.02^b

Erythrocyte (% total phospholipid) and serum (% total cholesterol ester and phospholipid) levels of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), arachidonic acid (AA), the ratio of EPA + DHA: AA, and the ratio of n-3: n-6 fatty acids. Statistically significant (P≤0.05) differences are indicated by different letters, e.g.: a group designated with is ^a different than a group designated with ^b; but two groups with ^b are not different.